Additive Orthopaedics received FDA 510(k) clearance to market Patient Specific 3D-Printed Bone Segments for ankle and foot fixation.
Per leadership, the company’s lattice structures have shown close to 90% bony ingrowth after 6 months, with no use of biologics.
Over 1,000 of the company’s devices have been implanted since commercial launch in early 2017. The company has recently closed a Series B round of US $1.0MM.
Additive Orthopaedics received FDA 510(k) clearance to market Patient Specific 3D-Printed Bone Segments for ankle and foot fixation.
Per leadership, the company's lattice structures have shown close to 90% bony ingrowth after 6 months, with no use of biologics.
Over 1,000 of the company's devices have been implanted since commercial launch...
Additive Orthopaedics received FDA 510(k) clearance to market Patient Specific 3D-Printed Bone Segments for ankle and foot fixation.
Per leadership, the company’s lattice structures have shown close to 90% bony ingrowth after 6 months, with no use of biologics.
Over 1,000 of the company’s devices have been implanted since commercial launch in early 2017. The company has recently closed a Series B round of US $1.0MM.
Copy to clipboard 
